IMPORTANT INFORMATION: The JUVÉDERM® range of injectable gels are medical devices for use in adults. JUVÉDERM® VOLITE contain 12mg/mL cross-linked hyaluronic acid with lidocaine 3mg/mL. JUVÉDERM® ULTRA XC and JUVÉDERM® ULTRA PLUS XC contain 24mg/mL cross-linked hyaluronic acid with lidocaine 3mg/mL. Juvéderm® VOLITE™ is for filling superficial depressions of the skin as well as for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM® ULTRA XC is for filling medium-sized depressions of the skin as well as for lip definition. JUVÉDERM® ULTRA PLUS XC is for filling mid and/or deep depressions of the skin as well as for lip definition and enhancement. All JUVÉDERM® products should be administered only by a trained medical professional. JUVÉDERM® ULTRA XC and JUVÉDERM® ULTRA PLUS XC™ should not be injected into the eyelids. You should not receive treatment with any JUVÉDERM® product if you are below 18 years of age, have untreated epilepsy, history of hypertrophic scars or porphyria, or if you are pregnant or breastfeeding, hypersensitivity to ingredients including hyaluronic acid, lidocaine or amide-type local anaesthetics, any areas of cutaneous inflammation and/or infections, or if you have just had laser treatment, deep chemical peel or dermabrasion. Precautions: Caution is required if you have received treatment with another dermal filler; if you have a history of or are currently suffering an auto-immune disease, severe multiple allergies, anaphylactic shock, streptococcal disease, symptoms of cardiac conduction disorders; or if you are taking certain medications including anti-coagulants or certain drugs that reduce/inhibit hepatic metabolism. Avoid makeup for 12 hours after injection and prolonged exposure to sunlight/UV light/extreme temperatures for 2 weeks. Adverse effects reported after treatment with JUVÉDERM® range of fillers have included immediate or delayed injection site inflammatory reactions (redness/swelling/ itching/pain on pressure) persisting a week post treatment, haematomas, induration or nodules, discolouration, weak filling effect, risk of infection, abscess formation, granuloma, necrosis or hypersensitivity. Please ask your medical professional or request for the Directions For Use for complete list of precautions and adverse effects per respective filler. JUVÉDERM® injectable gels are not funded on the New Zealand Pharmaceutical Scheme. You will need to pay for this treatment. Normal visit fees apply. Speak to your medical professional about your own situation and about the benefits/ risks of this procedure in appearance medicine. If you have any side effects or concerns speak to your doctor.  ®Trademark(s) and registered trademark(s) of Allergan, Inc. Allergan Australia Pty Ltd. 810 Pacific Highway, Gordon NSW 2072. ABN 85 000 612 831. Allergan New Zealand Limited, Auckland. © 2018 Allergan. All rights reserved. Date of preparation: October 2018 ANZ/0104/2017.

IMPORTANT INFORMATION: TEOSYAL RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 2, and TEOSYAL® PURESENSE ULTRA DEEP are trademark of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anaesthetic can induce a positive reaction to anti-doping tests). In the case of known hypersensitivity to lidocaine and/or amide local anaesthetic agents, we recommend not use lidocaine-containing products and please refer to products without lidocaine. They are class III medical device and are regulated health product bearing the CE marking (CE2797) under this regulation.

Local manifestations: inflammatory reactions (erythema, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, dyschromia, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke.

Please consult your physician or pharmacist for more information. Please refer to instructions for use

IMPORTANT INFORMATION: Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex, 300 or 500 IPSEN units) is a Prescription Medicine for the treatment of vertical frown lines between the eyebrows. DYSPORT® has risks and benefits. For more information, talk to your medical professional or read the Consumer Medicine Information available at www.medsafe.govt.nz. Ask your Doctor if DYSPORT® is right for you. Do not use in patients with allergIndividy to active ingredients, in patients diagnosed with myasthenic gravis. Do not use if there is sign of infection at injection site. If you experience side effects and they concern you, see your medical professional. You will need to pay for DYSPORT® and for the administration and consultation charges. Galderma c/o Healthcare Logistics, Auckland 0800 174 104.